Heart Failure

The purpose of this study is to investigate the safety and efficacy of empagliflozin versus placebo in patients with chronic heart failure with preserved ejection fraction.

Inclusion Criteria:

  • Diagnosed with chronic heart failure (HF)

  • Experiences shortness of breath when undertaking normal activities

  • Echocardiogram in past 18 months with ejection fraction >40%

  • Further inclusion criteria apply

Exclusion Criteria:

  • Myocardial infarction, coronary artery bypass graft surgery, or other major cardiovascular surgery, stroke or TIA (Transient Ischaemic Attack) in past 90 days prior to Visit 1

  • Implanted cardiac resynchronisation therapy

  • Currently enrolled in another investigational device or drug study

  • Currently taking SGLT-2 inhibitor or oral steroids

  • Atrial Fibrillation > 110 bpm

  • Systolic blood pressure > 180 mm Hg or < 100 mm Hg

  • Requires dialysis

  • Current or past history of malignancy within the past 2 years ( includes SCC)

  • Further exclusion criteria apply

Further information can be found at https://clinicaltrials.gov/ct2/show/NCT03057951